CADTH Reimbursement Review - Provisional Funding Algorithm - Indication: Renal Cell Carcinoma

The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] Retreatment with nivolumab should be at the discretion of the treating physician for patients who have discontinued nivolumab at the time of relapse and only if the treatment was discontinued before disease progression or disease progression occurred during a treatment break. [...] In the absence of evidence to confirm the efficacy and safety of cabozantinib in the first-line setting, pERC does not support the use of cabozantinib in patients who are intolerant to first-line VEGFR TKI. [...] Retreatment with nivolumab should be at the discretion of the treating physician for patients who have discontinued nivolumab at the time of relapse and only if the treatment was discontinued before disease progression or disease progression occurred during a treatment break.